DrugPatentWatch Database Preview

Patent: 10,101,343

« Back to Dashboard

Summary for Patent: 10,101,343

Title:	Anti-folate receptor alpha antibodies and uses thereof
Abstract:	Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, or lung cancer, using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of folate receptor alpha in a sample derived from a subject and comparing this level with the level of folate receptor alpha in a control sample or reference sample.
Inventor(s):	O\'Shannessy; Daniel John (Schwenksville, PA)
Assignee:	Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:	15/434,326
Patent Claims:	see list of patent claims

Details for Patent 10,101,343

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	HERCEPTIN	trastuzumab	VIAL; INTRAVENOUS	103792	001	1998-09-25		Eisai R&D Management Co., Ltd. (Tokyo, JP)	2031-07-15	RX	Orphan	search

International Patent Family for US Patent 10,101,343

Country	Patent Number	Estimated Expiration
Australia	2011323124
Australia	2012284321
Australia	2016203408
Australia	2017202365
Australia	2018201760